Business Description
Eiger BioPharmaceuticals Inc
NAICS : 325414
SIC : 2836
ISIN : US28249U1051
Description
Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.62 | |||||
Equity-to-Asset | -0.37 | |||||
Debt-to-Equity | -2.85 | |||||
Debt-to-EBITDA | -0.6 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -24.25 | |||||
Beneish M-Score | -3.25 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 10.4 | |||||
3-Year EPS without NRI Growth Rate | 9.8 | |||||
3-Year FCF Growth Rate | 9.2 |
Momentum Rank
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 44.47 | |||||
9-Day RSI | 43.89 | |||||
14-Day RSI | 43.6 | |||||
6-1 Month Momentum % | 27.95 | |||||
12-1 Month Momentum % | -77.49 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.71 | |||||
Quick Ratio | 0.68 | |||||
Cash Ratio | 0.48 | |||||
Days Inventory | 36347.92 | |||||
Days Sales Outstanding | 57.19 | |||||
Days Payable | 99620.67 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9.4 | |||||
Shareholder Yield % | -16.58 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 99.85 | |||||
Operating Margin % | -455.12 | |||||
Net Margin % | -475.26 | |||||
FCF Margin % | -474.61 | |||||
ROE % | -417.47 | |||||
ROA % | -97.05 | |||||
ROIC % | -439.77 | |||||
ROC (Joel Greenblatt) % | -6501.78 | |||||
ROCE % | -138.67 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 1.1 | |||||
EV-to-EBIT | -0.48 | |||||
EV-to-EBITDA | -0.48 | |||||
EV-to-Revenue | 2.1 | |||||
EV-to-FCF | -0.44 | |||||
Earnings Yield (Greenblatt) % | -208.33 | |||||
FCF Yield % | -431.27 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eiger BioPharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 14.625 | ||
EPS (TTM) (€) | -47.435 | ||
Beta | 0 | ||
Volatility % | 121.12 | ||
14-Day RSI | 43.6 | ||
14-Day ATR (€) | 0.001764 | ||
20-Day SMA (€) | 6.18 | ||
12-1 Month Momentum % | -77.49 | ||
52-Week Range (€) | 4.05 - 34.2 | ||
Shares Outstanding (Mil) | 1.48 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Eiger BioPharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Eiger BioPharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Eiger BioPharmaceuticals Inc Frequently Asked Questions
What is Eiger BioPharmaceuticals Inc(FRA:72C)'s stock price today?
The current price of FRA:72C is €6.18. The 52 week high of FRA:72C is €34.20 and 52 week low is €4.05.
When is next earnings date of Eiger BioPharmaceuticals Inc(FRA:72C)?
The next earnings date of Eiger BioPharmaceuticals Inc(FRA:72C) is 2024-07-18 Est..
Does Eiger BioPharmaceuticals Inc(FRA:72C) pay dividends? If so, how much?
Eiger BioPharmaceuticals Inc(FRA:72C) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |